mrgd  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Alomone Labs mrgd
    Changes in mean arterial pressure (MAP) with intravenous bolus injections of either <t>MasR</t> blocker A779 (10 μg/kg), <t>MrgD</t> blocker D-Pro (10 μg/kg) or AT2R blocker PD123319 (1 mg/kg) in CCl 4 (A) BDL (B) , and PPVL (C) models. Saline injection served as the control. Each time point represents the mean ± SEM profile from six to seven rats per treatment group. * p
    Mrgd, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mrgd/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mrgd - by Bioz Stars, 2022-12
    94/100 stars

    Images

    1) Product Images from "Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats"

    Article Title: Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats

    Journal: Frontiers in Physiology

    doi: 10.3389/fphys.2019.01169

    Changes in mean arterial pressure (MAP) with intravenous bolus injections of either MasR blocker A779 (10 μg/kg), MrgD blocker D-Pro (10 μg/kg) or AT2R blocker PD123319 (1 mg/kg) in CCl 4 (A) BDL (B) , and PPVL (C) models. Saline injection served as the control. Each time point represents the mean ± SEM profile from six to seven rats per treatment group. * p
    Figure Legend Snippet: Changes in mean arterial pressure (MAP) with intravenous bolus injections of either MasR blocker A779 (10 μg/kg), MrgD blocker D-Pro (10 μg/kg) or AT2R blocker PD123319 (1 mg/kg) in CCl 4 (A) BDL (B) , and PPVL (C) models. Saline injection served as the control. Each time point represents the mean ± SEM profile from six to seven rats per treatment group. * p

    Techniques Used: Injection

    Changes in mean arterial pressure after the treatment with AT1R blocker losartan (1 mg/kg) in the CCl 4 (A) and BDL (B) models. Note that the two groups that received losartan injections in each model were pooled for t-test analysis. Bottom panels show mean arterial pressure of the two losartan groups after receiving either MasR blocker A779 (10 μg/kg) or MrgD blocker D-Pro (10 μg/kg) in the CCl 4 (C) and BDL (D) models. Losartan significantly reduced MAP in all groups; however, A779 or D-Pro which was given 20 min after losartan failed to counteract the hypotensive effect of losartan. Each time point represents the mean ± SEM profile from 12 to 14 (A,B) or 6 to 7 (C,D) rats per treatment group. Data in (C) and (D) were analyzed by repeated-measures ANOVA. ** p
    Figure Legend Snippet: Changes in mean arterial pressure after the treatment with AT1R blocker losartan (1 mg/kg) in the CCl 4 (A) and BDL (B) models. Note that the two groups that received losartan injections in each model were pooled for t-test analysis. Bottom panels show mean arterial pressure of the two losartan groups after receiving either MasR blocker A779 (10 μg/kg) or MrgD blocker D-Pro (10 μg/kg) in the CCl 4 (C) and BDL (D) models. Losartan significantly reduced MAP in all groups; however, A779 or D-Pro which was given 20 min after losartan failed to counteract the hypotensive effect of losartan. Each time point represents the mean ± SEM profile from 12 to 14 (A,B) or 6 to 7 (C,D) rats per treatment group. Data in (C) and (D) were analyzed by repeated-measures ANOVA. ** p

    Techniques Used:

    Immunohistochemical localization of MasR (left column) and MrgD (right column) in the liver. MasR (C) and MrgD (D) staining of CCl 4 livers were compared with those of healthy control livers ( A,B , respectively). Note that in cirrhotic livers (C) , there was strong positive staining for MasR in liver sinusoids (arrow) which is consistent with the localization of hepatic stellate cells and/or liver sinusoidal endothelial cells. Also note that positive staining for MasR in bile duct epithelial cells (arrow head-large) and hepatic arterioles (arrow head-small) in the cirrhotic liver. However, there was no positive staining for MrgD in the cirrhotic liver (D) . Livers from PPVL rats showed no positive staining for both receptors (G,H) compared to the controls (E,F) . Original images were captured at the X20 magnification.
    Figure Legend Snippet: Immunohistochemical localization of MasR (left column) and MrgD (right column) in the liver. MasR (C) and MrgD (D) staining of CCl 4 livers were compared with those of healthy control livers ( A,B , respectively). Note that in cirrhotic livers (C) , there was strong positive staining for MasR in liver sinusoids (arrow) which is consistent with the localization of hepatic stellate cells and/or liver sinusoidal endothelial cells. Also note that positive staining for MasR in bile duct epithelial cells (arrow head-large) and hepatic arterioles (arrow head-small) in the cirrhotic liver. However, there was no positive staining for MrgD in the cirrhotic liver (D) . Livers from PPVL rats showed no positive staining for both receptors (G,H) compared to the controls (E,F) . Original images were captured at the X20 magnification.

    Techniques Used: Immunohistochemistry, Staining

    Receptor gene expression of MasR (A) , MrgD (B) , and AT1R (C) analyzed by qPCR in the livers of the CCl 4 , BDL, and PPVL rats compared with sham-operated and healthy control rats. Data have been normalized to endogenous control gene 18S, and healthy control group was given an arbitrary value of 1. Each time point represents the mean ± SEM profile from six to seven rats per treatment group.
    Figure Legend Snippet: Receptor gene expression of MasR (A) , MrgD (B) , and AT1R (C) analyzed by qPCR in the livers of the CCl 4 , BDL, and PPVL rats compared with sham-operated and healthy control rats. Data have been normalized to endogenous control gene 18S, and healthy control group was given an arbitrary value of 1. Each time point represents the mean ± SEM profile from six to seven rats per treatment group.

    Techniques Used: Expressing, Real-time Polymerase Chain Reaction

    Receptor gene expression of MasR (A) , MrgD (B) , and AT1R (C) analyzed by qPCR in mesenteric vascular bed of the CCl 4 , BDL and PPVL rats compared with sham-operated and healthy control rats. Data have been normalized to endogenous control gene 18S, and healthy control group was given an arbitrary value of 1. Each time point represents the mean ± SEM profile from six to seven rats per treatment group.
    Figure Legend Snippet: Receptor gene expression of MasR (A) , MrgD (B) , and AT1R (C) analyzed by qPCR in mesenteric vascular bed of the CCl 4 , BDL and PPVL rats compared with sham-operated and healthy control rats. Data have been normalized to endogenous control gene 18S, and healthy control group was given an arbitrary value of 1. Each time point represents the mean ± SEM profile from six to seven rats per treatment group.

    Techniques Used: Expressing, Real-time Polymerase Chain Reaction

    Changes in portal pressure (PP) after intravenous bolus injections of either the MasR blocker A779 (10 μg/kg), MrgD blocker D-Pro (10 μg/kg), or AT2R blocker PD123319 (1 mg/kg) in CCl 4 (A) , BDL (B) , and PPVL (C) models. Saline injection served as the control. Pressure measurement was commenced 5 min prior to injection and continued for 30 min after the injection. Each time point represents the mean ± SEM profile from six to seven rats per treatment group. **** p
    Figure Legend Snippet: Changes in portal pressure (PP) after intravenous bolus injections of either the MasR blocker A779 (10 μg/kg), MrgD blocker D-Pro (10 μg/kg), or AT2R blocker PD123319 (1 mg/kg) in CCl 4 (A) , BDL (B) , and PPVL (C) models. Saline injection served as the control. Pressure measurement was commenced 5 min prior to injection and continued for 30 min after the injection. Each time point represents the mean ± SEM profile from six to seven rats per treatment group. **** p

    Techniques Used: Injection

    Schematic representation of the renin angiotensin system (RAS) showing the pathways responsible for the generation of angiotensin II (Ang II) and angiotensin-(1-7) [Ang-(1-7)]. Ang II acts via its type 1 receptor (AT1R) to exert vasoconstrictive effects. Ang II is degraded to Ang-(1-7) by angiotensin converting enzyme 2 (ACE2). Ang-(1-7) opposes Ang II effects through its receptors, MasR and MrgD.
    Figure Legend Snippet: Schematic representation of the renin angiotensin system (RAS) showing the pathways responsible for the generation of angiotensin II (Ang II) and angiotensin-(1-7) [Ang-(1-7)]. Ang II acts via its type 1 receptor (AT1R) to exert vasoconstrictive effects. Ang II is degraded to Ang-(1-7) by angiotensin converting enzyme 2 (ACE2). Ang-(1-7) opposes Ang II effects through its receptors, MasR and MrgD.

    Techniques Used:

    Changes in portal pressure after the treatment with AT1R blocker losartan (1 mg/kg) in the CCl 4 (A) and BDL (B) models. Note that the two groups that received losartan injections in each model were pooled for t -test analysis. Bottom panels show portal pressure of the two losartan groups after receiving either MasR blocker A779 (10 μg/kg) or MrgD blocker D-Pro (10 μg/kg) in the CCl 4 (C) and BDL (D) models. Losartan significantly reduced portal pressure in all groups; however, A779 or D-Pro which was given 20 min after losartan failed to affect portal pressure. Each time point represents the mean ± SEM profile from 12 to 14 (A,B) or 6 to 7 (C,D) rats per treatment group. Data in (C) and (D) were analyzed by repeated-measures ANOVA. ** p
    Figure Legend Snippet: Changes in portal pressure after the treatment with AT1R blocker losartan (1 mg/kg) in the CCl 4 (A) and BDL (B) models. Note that the two groups that received losartan injections in each model were pooled for t -test analysis. Bottom panels show portal pressure of the two losartan groups after receiving either MasR blocker A779 (10 μg/kg) or MrgD blocker D-Pro (10 μg/kg) in the CCl 4 (C) and BDL (D) models. Losartan significantly reduced portal pressure in all groups; however, A779 or D-Pro which was given 20 min after losartan failed to affect portal pressure. Each time point represents the mean ± SEM profile from 12 to 14 (A,B) or 6 to 7 (C,D) rats per treatment group. Data in (C) and (D) were analyzed by repeated-measures ANOVA. ** p

    Techniques Used:

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Alomone Labs anti mrgprd gpcr tgr7 antibody
    The expression and functional activity of pain- and itch-related receptor <t>MrgprD</t> are upregulated in DRG neurons from oxazolone-induced ACD model mice. A Heatmap showing the expression of Mrgpr family genes identified in DRG of oxazolone versus control group mice. n = 4 mice per group. B qPCR validations of the expression of three itch- or pain-related Mrgpr genes, namely, Mrgprx1 , Mrgpra3 , and Mrgprd . n = 6–8 mice per group. * p
    Anti Mrgprd Gpcr Tgr7 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mrgprd gpcr tgr7 antibody/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti mrgprd gpcr tgr7 antibody - by Bioz Stars, 2022-12
    94/100 stars
      Buy from Supplier

    94
    Alomone Labs acc 061
    The expression and functional activity of pain- and itch-related receptor <t>MrgprD</t> are upregulated in DRG neurons from oxazolone-induced ACD model mice. A Heatmap showing the expression of Mrgpr family genes identified in DRG of oxazolone versus control group mice. n = 4 mice per group. B qPCR validations of the expression of three itch- or pain-related Mrgpr genes, namely, Mrgprx1 , Mrgpra3 , and Mrgprd . n = 6–8 mice per group. * p
    Acc 061, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/acc 061/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    acc 061 - by Bioz Stars, 2022-12
    94/100 stars
      Buy from Supplier

    Image Search Results


    The expression and functional activity of pain- and itch-related receptor MrgprD are upregulated in DRG neurons from oxazolone-induced ACD model mice. A Heatmap showing the expression of Mrgpr family genes identified in DRG of oxazolone versus control group mice. n = 4 mice per group. B qPCR validations of the expression of three itch- or pain-related Mrgpr genes, namely, Mrgprx1 , Mrgpra3 , and Mrgprd . n = 6–8 mice per group. * p

    Journal: Cellular & Molecular Biology Letters

    Article Title: Exploring neuronal mechanisms involved in the scratching behavior of a mouse model of allergic contact dermatitis by transcriptomics

    doi: 10.1186/s11658-022-00316-w

    Figure Lengend Snippet: The expression and functional activity of pain- and itch-related receptor MrgprD are upregulated in DRG neurons from oxazolone-induced ACD model mice. A Heatmap showing the expression of Mrgpr family genes identified in DRG of oxazolone versus control group mice. n = 4 mice per group. B qPCR validations of the expression of three itch- or pain-related Mrgpr genes, namely, Mrgprx1 , Mrgpra3 , and Mrgprd . n = 6–8 mice per group. * p

    Article Snippet: We used the following antibodies: rabbit anti-CD3 (1:200, no. MA1-90582, Thermo Fisher, USA), rabbit anti-MrgprD (1:200, no. AMR-061, Alomone, Israel), and mouse anti-NeuN (1:300, no. ab104224, Abcam, UK).

    Techniques: Expressing, Functional Assay, Activity Assay, Mouse Assay, Real-time Polymerase Chain Reaction